Why low-resolution data creates risks that high-resolution data can prevent.
EOP1 (End-of-Phase 1) and EOP2 (End-of-Phase 2) meetings are critical regulatory milestones where sponsors discuss development plans and evaluate study adequacy with the FDA.
Key evaluation areas include Phase 3 protocols, current study adequacy, pediatric safety plans, marketing application requirements, and CMC readiness.